VNDA (Vanda Pharmaceuticals) Other Current Receivables: $0.0 Mil (As of Mar. 2026)


VNDA Vanda Pharmaceuticals Inc VNDA
73 GF Score
Price $6.24
GF Value $5.54
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Other Current Receivables?

Vanda Pharmaceuticals VNDA -2.19% 73 Other Current Receivables is $0.0 Mil as of Mar. 2026. GuruFocus rates VNDA with a GF Score™ of 73/100 and a GF Value™ of $5.54 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Vanda Pharmaceuticals's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.0 Mil.

Vanda Pharmaceuticals Other Current Receivables Related Terms

Vanda Pharmaceuticals Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Other Current Receivables Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vanda Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
VNDA
73GF Score
Vanda Pharmaceuticals Inc VNDA
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.0 Mil mean?
Vanda Pharmaceuticals (VNDA) has a Other Current Receivables of $0.0 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Vanda Pharmaceuticals and its competitors.
Is Vanda Pharmaceuticals' Other Current Receivables too high?
Vanda Pharmaceuticals' current Other Current Receivables is $0.0 Mil. Overall, Vanda Pharmaceuticals has a GF Score™ of 73/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Other Current Receivables compare to AVIR and OABI?
Vanda Pharmaceuticals' Other Current Receivables of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Other Current Receivables is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (VNDA) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.54, compared to a current price of $6.24 — trading 12.6% above its estimated fair value. The current Other Current Receivables is $0.0 Mil. Vanda Pharmaceuticals' overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Vanda Pharmaceuticals (VNDA), the current Other Current Receivables is $0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (VNDA) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be overvalued. The current stock price of $6.24 is trading 12.6% above its estimated GF Value™ of $5.54. GuruFocus considers Vanda Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for VNDA:

  • Other Current Receivables: $0.0 Mil
  • GF Value™: $5.54 vs. price of $6.24 (12.6% above fair value)
  • GF Score™: 73/100 with 4 warning signs

No single metric tells the full story. See the VNDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges 0LKB:UKVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
73GF Score

Get the complete analysis for VNDA

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.24
Price
$5.54
GF Value